Latest Neurodegenerative Disease News

Page 7 of 7

Alterity Therapeutics Nears ATH434 Trial Results Amid Tight Cash Position

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Ada Torres

24 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026